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1.AIMS  
 
 
1. To analyse the pathological response rate following neoadjuvant 
chemoradiation in stage III breast cancer. 
  
2. To study the outcomes in terms of  disease free survival and 
overall survival.  
 
3. To determine the clinicopathological factors associated with 
pathological response and survival outcomes. 
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2.BACKGROUND 
 Locally advanced Breast cancer (LABC) is a heterogenous group 
of tumors with marked variation in outcome and high propensity for 
local, regional and distant failure. Hence integrated multimodality 
approach had become standard for optimal patient outcome. Neoadjuvant 
chemotherapy has evolved as the conventional and standard of care in 
treatment of LABC. Neoadjuvant chemoradiation is also a safe and valid 
multimodality treatment option for LABC.1,2,3,4 
 Neoadjuvant chemotherapy is established as standard treatment 
for LABC with varying pathological response rate.5 There is significant 
association between the extent of pathological response and longterm 
outcome in terms of disease free survival- DFS and overall survival-OS.6 
Neoadjuvant chemoradiation is associated with higher pathological 
response rate that translate in terms of survival benefit.  
 Shanta V, et al analysed one of the largest database containing 
1,117 LABC patients  treated with neoadjuvant concurrent 
chemoradiation during 1990 to 1999. The reported  clinical response rate 
was 91 % and complete pathological response rate  up to 33.7 %. 
Patients with complete pathological  response rate had long term 
survival. The DFS at 5, 10 and 15 years was 76.6%,69.6% and 63.6% 
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respectively. The corresponding overall survival was 86.5%, 78% and 
76.2%.7 
 Formenti et al reported  44 patients treated with  neoadjuvant 
twice weekly paclitaxel and concurrent radiotherapy had pathological 
response rate of 34% in the mastectomy specimen and 16% complete 
pathological response rate (clearance of invasive cancer in both breast 
and axilla) that translate in to better  survival outcomes.8  
Neoadjuvant concurrent chemoradiation for LABC was associated 
with acceptable morbidity and mortality.9 The most common toxicity 
reported was skin related toxicity.9,10 
 Ipsilateral involvement of supraclavicular node was considered as 
a poor sign with high risk of distant metastasis. Majority of them 
developed distant metastasis within 1 year and cure was rare. But with 
aggressive combined modality treatment , the outlook of these patients 
once considered metastatic stage IV disease with dismal outcomes had 
changed with longterm disease free and overall survival. Brito et al  
reviewed three prospective trials of combined-modality therapy for 
locally advanced breast cancer treated at M.D. Anderson Cancer Center 
between 1974 and 1991. Seventy patients with ipsilateral supraclavicular 
metastases with no evidence of other distant metastases were identified 
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and analysed. With median follow up of 11.6 years, the results were 
equivalent to stage III B disease but better than stage IV patients, in 
terms of local control rate and survival (DFS and OS). They strongly 
recommend aggressive combined modality treatment for LABC with 
ipsilateral supraclavicular node involvement without distant metastasis.11  
 Multimodality treatment strategy is now the standard of care for 
LABC and neoadjuvant chemotherapy  has been established worldwide. 
In our institute, we practice multimodality treatment for breast cancer 
since 1960. All LABC patients now receive uniform protocol with 
neoadjuvant concurrent chemoradiation followed by surgery and then 
completion of adjuvant chemotherapy and hormone therapy based on 
receptors. Studies had shown that the pathological response after 
neoadjuvant chemotherapy or chemoradiation protocol was high with 
better survival outcome. Earlier study from our institute and recent 
reports from United States had shown better outcomes in terms of 
survival benefit for patients who achieved pathological complete 
response after neoadjuvant chemoradiation treatment7,8.  
 Apart from our institute there are very few reports on this uniform 
preoperative concurrent chemoradiation protocol for locally advanced 
breast cancer management. Hence we decided to analyse the 
pathological complete response rate and its impact on survival and to 
determine the clinicopathological factors associated with it. 
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3.MATERIALS AND METHODS 
Previously untreated biopsy and cytology proven 831 stage III 
breast cancer patients treated at our institute between 2006 and 2008 
with neoadjuvant concurrent chemoradiation were taken and 550 patients 
who had surgery after the neoadjuvant concurrent chemoradiation 
protocol were included in the study for analysis. All patients were 
clinically staged by IUCC- TNM 2002 classification system, Stage III 
(A, B, C).12 
Study design: Retrospective study 
3.1.Statistical analysis methods:  
 Frequency table described the various clinico-pathological factors, 
treatment response and outcomes. The survival difference was estimated 
by log-rank test and the statistical significance between the pCR and 
clinic-pathological factors by Pearson-Chi square test. Overall survival is 
defined as time from the date of diagnosis to date of death by any cause 
and disease free survival rate is the time from date of diagnosis to date of 
any  loco-regional or distant recurrence or death. 
3.2.Inclusion criteria : 
1. Stage III breast cancer without prior treatment  
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3.3.Exclusion criteria:  
1. Inflammatory breast cancer 
2. Stage III breast cancer treated outside with chemotherapy or 
surgery (Excision biopsy or lumpectomy or simple mastectomy or 
modified radical mastectomy) 
3. Not fit for chemoradiation  
3.4.Management protocol: 
 The staging work-up included mammography, chest radiography, 
bone scan, ultrasonography of abdomen and pelvis, CT chest. All 
patients had biopsy or cytology proven diagnosis of breast carcinoma 
and cytology proven nodes if feasible. Receptor status and prognostic 
markers were also documented. Eligible patients received neoadjuvant 
concurrent chemoradiation according to the institute protocol, then are 
reassessed to undergo surgery and complete the remaining 
chemotherapy. Postoperative surgical specimen was processed according 
to the protocol and pathological response to neoadjuvant concurrent 
chemoradiation was assessed. 
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3.5.Treatment protocol:  
 All patients received neoadjuvant concurrent chemoradiation. 
Chemotherapy was administered every 3 weeks using one of the 
regimens- CMF/FEC/FAC/TE. Radiotherapy was delivered to breast and 
regional node along with chemotherapy after the completion of first   
chemotherapy cycle. Dose of radiation was 40 Gy in 180-200 cGy per 
fraction, 5 days/ week (Monday through Friday). Radiation was not 
usually delivered on the day of chemotherapy. A break in radiation 
occured if patient had treatment related toxicity. Patients were assessed 
once a week during chemoradiation, before each cycle of chemotherapy 
and at the end of chemoradiation for tumor response and toxicity. Total 
blood count was done twice weekly and whenever necessary. 
Hematological toxicity was recorded and normal tissue reactions were 
graded according to the RTOG toxicity criteria.  
3.6.Radiotherapy:  
 Cobalt 60 beam was used to deliver radiation to the target areas 
which include involved breast, ipsilateral axilla  and supraclavicular 
region. Internal mammary region was included in some patients. 
Treatment was delivered at a source skin distance of 80 cm. 
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3.7.Breast RT:  
Patient was immobilised and arm maintained in abducted position. 
Radiation was delivered to breast using two tangential medial and lateral 
fields at an angle of 60 degrees and 120 degrees.  
Upper border   - inferior border of the clavicle 
Medial border  - midline 
Lateral border   - mid- axillary line 
Inferior border  - 2 cm below the infra mammary fold  
Dose was prescribed at the center of the tumor, computing the dose from 
medial and lateral fields. Total dose was 40Gy in 20 fractions, 5 days per 
week. 
3.8.SCL and Axillary RT: Combined field was used for SCL and axilla. 
 3.9.SCL radiation- Single direct field of size 15 x 10 cm (approximate) 
and the dose was calculated at 3 cm depth. Daily dose was 200cGy/day 
and total dose was 40Gy in 20 fractions, 5 days per week.  
3.10.Axillary radiation - The dose contribution from the both tangential 
fields was measured at the midpoint of axilla and 3 cm from the 
tangential field’s superior border. Posterior axillary boost was delivered 
with the patient in prone position, approximate field size is 8 x 10 cm 
and total dose was 40Gy in 20 fractions, 5 days per week. Field size and 
bolus requirement were individualised. 
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3.11.Internal mammary RT:  Radiation to internal mammary region 
was delivered as indicated after surgery. It consists of a standard field 
size of 6x15 cm, extending from supra sternal angle up to xiphi-sternum 
and the field width was 6 cm extending 4 cm ipsilateral and 2cm across 
the midline. 
3.12.Chemotherapy schedule: 
Table 1.  
REGIMEN DRUGS DOSE ROUTE DAYS 
CMF Cyclophosphomide 600 mg/m2 Iv Day 1 
3 weekly Methotrexate 50 mg/m2 Iv Day 1 
 5-Fluro-Uracil 600 mg/m2 Iv Day 1 
     
FAC 5-Fluro-Uracil 600 mg/m2 Iv Day 1 
3 weekly Adriamycin 40 mg/m2 Iv Day 1 
 Cyclophosphomide 600 mg/m2 Iv Day 1 
     
FEC-60 5-Fluro-Uracil 600 mg/m2 Iv Day 1 
3 weekly Epirubicin 60 mg/m2 Iv Day 1 
 Cyclophosphomide 600 mg/m2 Iv Day 1 
     
TE Epirubicin 60 mg/m2 Iv Day 1 
3 weekly Paclitaxel 175 mg/m2 Iv Day 1 
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3.13.Hormonal therapy: All premenopausal women received 
Tamoxifen 10mg twice or 20 mg once daily and postmenopausal patients 
received Letrazole 2.5 mg once daily after completing the adjuvant 
chemotherapy based on the receptor status. 
3.14.Surgery: After completion of concurrent chemoradiation patients 
were reassessed 4 weeks after the end of radiotherapy (stage IIIA, IIIB) 
for appropriate surgery (modified radical mastectomy) based on the skin 
condition. For stage IIIC LABC, patients were followed up regularly for 
6 months after neoadjuvant chemoradiation. Those patients with no 
progression of disease and no metastasis were taken up for surgery.  The 
remaining chemotherapy was administered after 3 to 4 weeks of surgery 
and radiotherapy to supraclavicular or internal mammary region as 
indicated. All premenopausal receptor positive patients were offered 
bilateral salpingo-opherectomy at the time of modified radical 
mastectomy. Surgical specimen was processed, prepared and assessed 
with consistent protocol by pathology department and reporting done. 
Pathological complete response (pCR) was defined as absence of any 
microscopic evidence of invasive tumor in the breast and axillary nodes. 
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3.15.Follow up: During follow-up, patient was followed every third 
month for first 3 years and then every six months for the 4th and 5th year, 
then annually. At each visit a detailed clinical history was taken and 
physical examination was done. Annual investigations with chest X-ray, 
ultrasonography abdomen and pelvis, contralateral breast mammography 
were done routinely but bone scan and CECT scan were done as 
warranted. 
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4.REVIEW OF LITERATURE 
Breast cancer is a global problem and it contributes for a quarter 
of all cancers worldwide. The International Agency for Research on 
Cancer (IARC) the specialized cancer agency of the WHO had released 
the latest information on incidence, prevalence and mortality worldwide. 
GLOBOCAN 2012 the latest online database version of IARC‘s 
provides the recent estimate of global cancer burden across 184 countries 
worldwide for 28 types of cancer. Breast cancer is the most frequently 
diagnosed cancer among women in 140/184 countries. Since 2008 the 
incidence of breast cancer has increased by more than 20% and the new 
cases of breast cancer diagnosed in 2012 was 1.7 million (11.9%) 
worldwide. The incidence is highest in developed countries than the 
developing countries. In developed countries like Western Europe, North 
America, Australia, New Zealand the incidence is more than 90 per 1 
lakh women annually, compared to 30 in east Africa and some Asian 
countries.13 
 Madras Metropolitan Tumor Registry (MMTR) at the Cancer 
Institute was established in 1982, the crude incidence rate (CIR) of 
breast cancer increased from 14.3 (1982) to 34.2 (2010). In India the 
incidence is high among the urban than the rural population, highest in 
Chennai followed by Mumbai, Delhi and Bangalore.14  
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 Breast cancer is the leading cause of death among women 
worldwide in 201213. In the west, death rate from breast cancer is 
declining despite increasing incidence. The annual reduction in mortality 
is 1.7% in North America since 1992 and 0.98% in the last decade 
among European Union. The decline in mortality is owing to the 
increase in early diagnosis and improved efficacy of adjuvant therapies. 
In developing countries and underserved areas of developed countries 
the scenario is different with high death rates, due to delay in diagnosis 
because of restricted health care access and difference in  biology of the 
disease. WHO statistics reveals that the two components of early 
detection, namely education and screening programmes have reduced the 
mortality. For example in UK and US the reduction in breast cancer 
mortality was 12-13 lives per day.13,15 
4.1.Breast cancer therapy evolution:  
 Breast cancer, one of the most common disease of women had 
captured the attention throughout the ages. The earliest known case of 
breast cancer was reported in 1600 BCE from the Edwin Smith Papyrus, 
Egypt.16 Breast cancer therapy started with Leonides, a Greek physician 
who was credited with the first breast cancer operative treatment in the 
first century AD. Breast cancer surgery had a dramatic change in the 
14 
nineteenth century with the introduction of anaesthesia by William 
Morton in 1846 and the principle of antisepsis by Joseph Lister in 1867. 
 In the late 19th century, Sir William Halstead from Philadelphia, 
John Hopkins Hospital Medical School revolutionised the breast cancer 
treatment with his radical enbloc mastectomy which was unchallenged 
for 70 years, until modified by Patey in 1940. Halsteadian concept put 
forth in 1890 said that breast cancer was a localized disease to start with 
and then spread in a predictable and orderly manner to the regional nodal 
basin and then to systemic circulation.17 
 In twentieth century, Halsteadian radical mastectomy was 
challenged and the concept of lesser radical surgery, modified radical 
mastectomy was established with similar survival rates.  
Since 1970 the contemporary trend of breast conservation surgery had 
evolved and validated through a series of carefully designed and well 
conducted controlled clinical trails through National Surgical Adjuvant 
Breast and Bowel Project (NSABP).  
 Bernard Fischer in 1980, put forth his theory that breast cancer 
was a systemic disease to start with and the treatment needed to be 
therefore directed to systemic therapy.18 
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 Samuel Hellman in 1994, put forth his theory of “Spectrum 
Hypothesis” which states that breast cancer was a spectrum of diseases 
with one end of the spectrum being localized disease and the other end 
being systemic disease. Now, based on this hypothesis the breast cancer 
treatment targeted the local and the systemic components according to 
the stage of the disease.19 
4.2.Locally advanced breast cancer: 
 LABC is a public health problem and poses challenges in the 
management worldwide. The incidence among the newly diagnosed 
cases were 40% to 60% in many developing and underserved developed 
countries.  
 Traditionally LABC included breast cancer of any size with 
skin and chest wall involvement20. The management of LABC had 
evolved in recent three decades. Historically surgery or radiotherapy 
alone had poor prognosis with high recurrence and death.   
LABC includes  
 T3 (>5cm- TNM staging) 
 Any size with skin and chest wall involvement 
 Fixed or matted axillary nodes (N2) 
 Ipsilateral supraclavicular or subclavicular nodes (N3) 
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Haagensen and Stout inoperability critera includes21 
1. Extensive skin edema ( >50% skin involved) 
2. Satellite skin nodules 
3. Inflammatory type of cancer 
4. Clinically involved Supra clavicular or Internal Mammary nodes 
5. Edema of arms 
6. Any TWO of the following grave signs: 
a. Skin ulcer 
b. Skin edema of limited extent (less than one-third of the skin 
over the breast involved) 
c. Tumor fixity to chest wall 
d. Axillary lymph nodes size 2.5 cm, or more, in transverse 
diameter and proved to contain metastases by biopsy 
e. Axillary lymph nodes fixity to the skin or the deep 
structures 
 Inoperable LABC treated with radiotherapy were associated with 
high complication rates with significant local control rate but the overall 
cure rate remained unchanged. 
 Combined modality treatment approach evolved in recent three 
decades, incorporating surgery, radiotherapy and systemic therapy and it 
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represented the standard of care for LABC. Multimodality treatment 
strategy included preoperative chemotherapy with theoretical advantages 
like early institution of systemic therapy, in vivo tumor response 
assessment, reduction in the size of primary tumor and lymph nodes. 
Despite the disadvantages like delay in local therapy, drug resistance, 
unreliable clinical staging for preoperative chemotherapy strategy, the 
clinical advantages of response assessment and possible breast 
conservative surgery were worth the use of neoadjuvant therapy. 
 Response to neoadjuvant chemotherapy both clinical and 
pathological  rates were varying with chemotherapy regimens used. 
 In literature, the pathological response rate was reported to be 10-
20% for anthracyclin based regimen and higher for taxane and 
trastuzumab based regimen. There was no optimal tool for clinical 
measurement of the tumor response. Imaging methods were more 
reliable than the clinical examination which were inaccurate and with 
inter-individual variations. Combination of both clinical and imaging 
methods was almost equivalent to the histopathological response. MRI, 
PET-CT and other newer modalities are under investigation, needs 
validation to incorporate in to the clinical practice.  
 Pathological complete response after neoadjuvant therapy was a 
prognostic factor which improved the long term survival.  
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 Pathological complete response was a surrogate for survival but 
not prognostic for DFS and OS in all subtypes of breast cancer22. 
Recently conducted German and Global FDA meta-analysis had 
established that luminal A(HR+, grade 1or2) and luminal B(HR and 
Her2 positive) subtypes have less favourable outcome for patients with 
pCR. Luminal B(HR+, grade 3, Her2 negative), Her2 positive and triple 
negative subtypes  had better outcomes on patients who achieved pCR 
than without pCR. Based on the meta-analysis information the three 
subtypes (Luminal B- HR+ grade 3, Her2 positive and triple negative) 
which were considered aggressive with poor prognosis had favourable 
prognosis if they achieved pCR.23 
 Various definitions for pCR have been proposed in the literature 
as follows 
 1.ypT<1a ypN+/- 
 2.ypTis ypN0+/- 
 3. ypT0 ypN0+/- 
In FDA global meta-analysis the distribution varies  
 1.ypTis ypN0     - 5% 
 2.ypT0/is ypN+  -  4%       
3.ypT0 ypN0      -  13% 
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 German meta-analysis have established that patients with ypT0 
ypN0- pCR had significant outcomes in terms of DFS and OS. FDA 
meta-analysis showed that between (ypTis ypN0) and (ypT0 ypTN0)- 
pCR, no relevant difference in event-free survival and OS.  Both meta-
analysis concluded that both (ypTis ypN0) and (ypT0 ypTN0) definitions 
are appropriate definitions for pCR in routine care and clinical trails22,23. 
 Pathological complete response rate vary with different 
neoadjuvant therapy and depends on the receptor status. Generally pCR 
was higher with receptor negative tumor and unknown in receptor  
positive tumor. It was rare after neoadjuvant endocrine therapy and 
highest with combination of chemotherapy and trastuzumab.  
 Newer chemotherapy combinations like anthracyclin with taxanes 
(Epirubicin + paclitaxel or Doxorubicin + Docetaxal) yield overall 
response rate 80-95% and modestly higher clinical and pathological 
complete response when compared to older regimens. NSABP-27 trial 
had shown that sequential chemotherapy regimen with doxorubicin 
followed by taxanes (AC - Docetaxol) had higher overall response with 
significant pCR rates. Further it showed improvement in breast 
conservation and borderline survival benefits. Recent trials with targeted 
therapy in combination with neoadjuvant  chemotherapy  yielded higher 
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pCR upto 65%24. In the NOAH (NeoAdjuvant Herceptin) study 
trastuzumab combination increased the pCR rate by 20 % with 
significant improvement in event-free survival. Based on this trail the 
European Medical Agency had approved trastuzumab for neoadjuvant 
treatment24. GeparQuinto trial compared lapatinib combination with 
trastuzumab and chemotherapy which showed a trend towards low pCR 
rate25. Neosphere study showed higher pCR rate for docetaxel + 
trastuzumab + pertuzumab combination26. 
4.3.BCS in LABC: 
 BCS is feasible in a carefully selected subgroup of LABC patients 
after neoadjuvant therapy. 
Selection criteria 
1. Healing of skin ulceration 
2. No skin or chest-wall fixation 
3. Complete resolution of skin edema 
4. Adequate reduction in tumor size 
5. No collagen vascular disease 
6. No extensive intramammary lymphatic invasion 
7. Absent extensive suspicious microcalcifications 
8. No evidence of multicentric tumor 
9. Clear surgical margins 
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 The outcomes in terms of local recurrence and 10 years overall 
survival in LABC patients undergoing BCS was equivalent to the BCS in 
early stage breast cancer. Skin involvement was not an absolute 
contraindication for BCS. Studies conducted by Shen et al 2004 and 
Guth et al 2005 had shown that BCS is feasible in LABC with 
noninflammatory skin involvement without affecting the local recurrence 
or survival rate and the outcomes are similar to the LABC patient 
without skin involvement27,28. Hence Guth et al suggested that non-
inflammatory skin involvement LABC should be classified based on the 
tumor size and nodal status and T4- TNM should be revised. At our 
institute we do not offer BCS for stage III LABC. 
4.4.Radiation role in LABC: 
 LABC is known for its high loco regional recurrence and systemic 
failure29. Internal mammary nodal involvement risk is up to 25 % in 
LABC30. Hence the need for loco regional control to target the occult 
tumor is achieved by the addition of radiotherapy. Radiation improves 
the local control and overall survival in stage III breast cancer. In stage 
IIIa, IIIb and IIIc with no gross residual tumor the local control rate is up 
to 90% with combined modality treatment31. 
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4.5.Sequencing Multimodality treatment: 
 LABC is fraught with higher distant metastasis hence early 
systemic therapy (eg-neoadjuvant chemotherapy) is warranted to control 
systemic failure. The impact on local and distal control for chemotherapy  
and radiotherapy whether delivered simultaneously or sequentially 
remains to be established32,33. Most of the combined modality treatment 
strategy for inoperable LABC follows neoadjuvant chemotherapy – 
surgery – adjuvant chemotherapy - radiotherapy  sequence31. 
 Recent strategy is to complete all cycles of chemotherapy before 
surgery and to use two sequential neoadjuvant chemotherapy 
regimen34,35. This new strategy is based on the following observations. 
1. Response monitoring and if no response or progression, a non-
cross resistant chemotherapy agent is introduced. 
2. The benefit of another non-cross resistant chemotherapy agent is 
irrespective of the response. 
The benefits of this new strategy are 
 1. Increase in overall response and pCR rates  
 2. Reduce the drug resistance 
 The addition of targeted agent Trastuzumab with the neoadjuvant 
chemotherapy had shown better response and outcomes. It has increased 
the overall response rate, pCR rate and locoregional control. 
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 The neoadjuvant concurrent chemoradiation has shown better 
local regional control and survival outcomes. 
 The demerits of concurrent chemoradiation given in the neoadjuvant 
settings are33 
1.Slight increase in hematological toxicity 
2.Acute radiation effects(skin toxicity) 
3.Impairs cosmetic results of BCS 
4.Cardiac toxicity in left side carcinoma breast 
 The combined modality treatment for LABC is a well tolerated 
modality with no increased surgical complications36. 
4.6.Survival effects: 
 Multimodality treatment benefits LABC in terms of survival. In 
stage III breast cancer trials have shown significant relapse free survival 
and overall survival benefit with multimodality treatment37,38,39,40,41. 
There are no randomized control trails comparing neoadjuvant with 
adjuvant chemotherapy in stage III breast cancer. But studies have 
shown equivalent survival benefit for stage III cancers whether 
chemotherapy delivered preoperatively or postoperatively42,43,44,45,46,47. 
4.7.Role of Pathologist - Specimen processing and reporting: 
 The pathologist play a vital role in the pathological assessment of 
response. With the advent of multimodality treatment, the pathological 
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examination of the specimen after neoadjuvant therapy is quite 
challenging. Clinical and radiological assessment under-estimate or 
over- estimate the residual tumor, hence the gold standard pathological 
examination is key in the assessment of pathological response. 
 Currently there are no standard criteria for classifying pCR, 
various systems are reported in the literature with different criteria to 
categorize the treatment response. Most of the system define pCR as 
absence of invasive cancer in the breast. 
4.8.Criteria in various Systems - Categorizing treatment response 
NSABP B-1848 
pCR-  No recognizable invasive tumor cells present  
pPR - The presence of scattered individual or small   
 clusters of tumor cells in a desmoplastic or hyaline  
 stroma 
pNR-  Tumors not exhibiting the changes listed above 
Miller-Payne System49 
Grade 1  No change or some alteration to individual    
  malignant cells, but no reduction in overall    
  cellularity (pNR) 
Grade 2  A minor loss of tumor cells, but overall cellularity   
  still high; up to 30% loss (pPR)  
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Grade 3  Between an estimated 30% and 90% reduction in   
  tumor cells (pPR)  
Grade 4  A marked disappearance of tumor cells such that   
  only small clusters or widely dispersed individual   
  cells remain; 90% loss of tumor cells (almost pCR)  
Grade 5  No malignant cells identifiable in sections from the  
  site of the tumor; only vascular fibroelastotic stroma  
  remains, often containing macrophages; however,   
  ductal carcinoma in situ may be present (pCR) 
Chevallier Method50 
Class 1  Disappearance of all tumor (pCR) 
Class 2  Presence of DCIS in the breast, no invasive    
  carcinoma and negative lymph node (pCR)  
Class 3  Presence of invasive carcinoma with stromal   
  alteration (pPR)  
Class 4  Few modifications of the tumoral appearance (pNR)  
Sataloff Method51 
Tumor  
T-A  Total or near total therapeutic effect (pCR)  
T-B  50% therapeutic effect, but less than total or near total  (pPR)  
T-C  50% therapeutic effect, but effect evident (pPR)  
T-D  No therapeutic effect (pNR)  
26 
Nodes  
N-A  Evidence of therapeutic effect, no metastatic disease  
N-B  No nodal metastasis or therapeutic effect  
N-C  Evidence of therapeutic effect, but nodal metastasis  present  
N-D  Viable metastatic disease, no therapeutic effect  
RCB System52 
RCB-0  No carcinoma in breast or lymph node (pCR)  
RCB-I  Partial response  
RCB-II  Partial response  
RCB-III  Chemoresistant  
AJCC ‘‘y’’ Classification53  
Category  T  Uses same criteria as before treatment  
  N  Uses same criteria as before treatment 
4.9.Sampling of tumor bed:  
 There is no established number of samples to be taken from the 
tumor bed, atleast one block per cm of the pretreatment tumor size is 
reasonable. If tumor residue is present, no additional sampling is 
required and if tumor residue is small entire area is submitted or if size 
more than 5 cm , atleast 5 sections are taken from the tumor residue. If 
no residue, number of additional samples to be done not yet established. 
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4.10.Microscopic appearance of tumor bed: 
1. Area of hyalinized vascular stroma with stromal edema and 
fibroelastosis but no normal glandular ducts or lobules. 
2. Stromal infiltration with foamy histiocytes, lymphocytes and 
hemosiderin pigments. 
3. Area of necrosis leaving nodules of histiocytes and cholesterol 
clefts. 
Cytological features mostly do not show changes except reduction in 
cellularity. DCIS shows no alteration after treatment. In difficult cases 
IHC correlation helpful in identifying the residual tumor and surgical 
margins by differentiating the epithelial cell(cytokeratin AE1/AE3/7) 
from the histiocytes(CD 68, CD 163). 
4.11.Post-treatment nodal evaluation: 
 Lymphnode response are difficult to assess after neoadjuvant 
therapy since fibrotic and atrophic changes are extensive. Nodes are 
completely submitted and thin sections are taken for pathological 
assessment. Nodal response may be classified as positive nodes or 
negative nodes with evidence of treatment changes or negative nodes 
without treatment changes. Lymph node metastasis that show complete 
response to treatment are characterized by hyaline stromal scar, mucin 
pools, histiocyte aggregates with no viable tumor. 
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4.12.Reporting: 
Breast Specimen 
1. Presence and size of the tumor 
2. Residual tumor size and extent 
3. Residual tumor bed- average cancer cellularity 
4. Residual tumor appearance and grade 
5. Viability 
6. Lymphovascular invasion 
7. DCIS presence and extent 
8. Margin status 
9. Overall response comment 
Lymph node status 
1. Number 
2. Size of the largest metastatic node 
3. Extranodal extension  
4. Number of metastatic node with evidence of treatment 
response 
5. Number of nodes with evidence of treatment response but 
without tumor cells. 
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4.13.FIGURE  
GROSS SPECIMEN 
 
 
 
Figure 1.Mastectomy specimen showing grossly visible fibrotic tumor  
bed without residual tumor. 
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4.14. FIGURE 
MICROSCOPY: pCR 
 
 
 
Figure 2. (Hematoxylin-eosin , magnification 20x) Complete 
pathological response showing histiocytes within the tumor bed. 
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5.RESULTS 
5.1.AGE DISTRIBUTION: 
  In our study 91%(501)  population were more than the 35 years of 
age and only 9%(49) were less than 35 years.  
 
Figure 3. Pie chart representing the age distribution 
Age > 35 years -  91 %   
Age < 35 years -  9% 
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5.2.MENOPAUSAL STATUS:  
Postmenopausal women were higher 56% (306) than the premenopausal 
32% (176) and  perimenopausal 12% (68) women. 
 
 
 
Figure3. Pie chart representing the menopausal status 
 
Premenopausal    -  32%  
Perimenopausal  -   12 
Postmenopausal  -   56% 
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5.3.STAGE DISTRIBUTON:  
Among the study population 346 (63%) were stage IIIA, 190 (34.5%) 
were stage IIIB and 14(2.5%) were stage III C. 
 
IIIA
IIIB
IIIC
63% 
34.50% 
2.50% 
STAGE 
IIIA IIIB IIIC
 
Figure 4. Column showing stage III breast cancer distribution. 
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5.4.HORMONAL RECEPTOR STATUS: 
56% 
44% 
RECEPTOR STATUS 
Positive Negative
 
Figure 5. Pie Chart representing the receptor  status  distribution.  
ER+  PR+        223 (40%)   
ER+  PR-        62 (11%), 
ER-   PR+        25 (5%) 
ER-   PR-        240(44%) 
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5.5.HISTOPATHOLOGY TYPES:  
The most common histology was infiltrating ductal carcinoma. 
Infiltrating ductal Carcinoma   - 67% 
Infiltrating mammary Carcinoma  - 3% 
Infiltrating lobular Carcinoma   - 1% 
FNAC positive     - 27% 
Others      - 2% 
 
Figure 6. Pie chart representing the histopathological types 
 
 
 
67%
1%
3%
2%
27%
HISTO-PATHOLOGY TYPES
INFILTRATING DUCTAL CA
INFILTRATING LOBULAR CA
INFILTRATING MAMMARY CA
OTHERS
FNAC POSITIVE
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5.6.GRADE OF THE TUMOR: 
327 (59%) patients had grade 3 and 217(40%) had grade 2 tumors. 
 
 
Figure 7. Pie Chart representing the tumor grade distribution. 
Grade I – 1%  
Grade II – 40%  
Grade III – 59% 
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5.7.CHEMOTHERAPY REGIMEN: 
FAC was the most common regimen used in 62% of patients. 
 
 
Figure 8. Pie Chart showing the different  chemotherapy regimen used 
in the breast cancer treatment protocol. 
FAC – 62%  
FEC - 20%  
CMF- 15%  
TE   - 3% 
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5.8.TREATMENT TOXICITY: 
 Skin toxicity was the most commonly encountered treatment toxicity. 
Grade 2 dry skin desquamation was seen in 353 (64%) patients. 
Hematological toxicity with low counts - grade 2 in 14% and grade 3 in 
15% were  reported. Treatment delay during concurrent chemoradiation, 
more than 2 weeks were observed in 5 % due to skin and hematological 
toxicities. No treatment toxicity related death reported. 
 
COUNTS SKIN TOXICITY
GRADE IV 1.50% 1%
GRADE III 15.00% 3.00%
GRADE II 14.00% 64.00%
GRADE I 1.00% 25.00%
NIL 68.50% 7.00%
0%
10%
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60%
70%
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90%
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Figure 9. Column representing the hematological and skin 
complications. 
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5.9.CLINICAL RESPONSE: 
Overall response rate -  97% 
Clinical complete response was achieved in 115 (21%) patients and 
partial response in 418 (76%) with 17 (3%)  patients had stable disease.  
 
 
Figure 10. Pie Chart showing the distribution of clinical responses to the 
neoadjuvant concurrent chemoradiation protocol. 
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5.10.POST SURGICAL COMPLICATIONS: 
No life threatening complications were encountered. Seroma was the 
most commonest morbidity reported in 109 (19.8%) patients which was 
managed conservatively. Eleven patients (2%) required skin grafting for 
necrosis of the wound. Wound infection rate was 5%. Upper limb 
lymphedema developed in fourteen patients (2.5%). 
61%
19.80%%
7.50%
5.00%
2.50%
2.00%
2.00%
0.20%
0.00% 20.00% 40.00% 60.00% 80.00%
NIL
Seroma
SEC SUTURING
WOUND INFECTION
LYMPHEDEMA
NECROSIS
SSG
GAPING
MORBIDITY
MORBIDITY
 
Figure 11. Bar Chart representing the surgery related morbidity. 
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5.11.PATHOLOGICAL RESPONSE: 
Pathological complete response was achieved in 139 patients (25%). 
25%
75%
PATHOLOGICAL RESPONSE
pcR No pcR
 
 
Figure12. Pie Chart representing the pathological response rate. 
 
 
 
 
Table 2. DISTRIBUTION OF pCR & NON-pCR SUBSETS: 
RESPONSE NUMBERS PERCENTAGE 
ypT0 N0 139 25% 
ypTis N0 9 1.5% 
ypT+ N0 184 33.5% 
ypT+ N+ 193 35% 
ypT0 N+ 25 4.5% 
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5.12.HORMONE THERAPY: 
 
30%
28%
2%
40%
TAMOXIFEN LETRAZOLE ANASTRAZOLE NONE
HORMONAL THERAPY
HORMONAL THERAPY
 
Figure 13. Column showing the percentage of various hormone agents 
used. 
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5.13.PATIENT STATUS AND RECURRENCE PATTERN: 
61% 
29% 
7% 3% 0%
10%
20%
30%
40%
50%
60%
70%
ALIVE WITHOUT
DISEASE
DEATH LOST TO FOLLOW UP ALIVE WITH DISEASE
PATIENT STATUS
2% 
1% 
22% 
75% 
LOCAL
LOCO-REGIONAL
SYSTEMIC
NIL
RECURRENCE PATTERN 
RECURRENCE PATTERN
 
Figure 14. Column and Bar charts showing the patient status and 
recurrence pattern. 
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5.14. SURVIVAL - STAGE III 
Stage IIIA – DFS   65% ,  OS   71% 
Stage IIIB – DFS   53% ,  OS   62% 
Stage IIIC – DFS   46%,   OS   50% 
 
0.00%
20.00%
40.00%
60.00%
80.00%
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A
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IIIA IIIB IIIC
DFS 65.00% 53.00% 46.00%
OS 71% 62% 50%
Chart Title 
 
Figure 15. Bar chart diagram showing the survival- DFS and OS 
distribution in stage III breast cancer. 
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5.15.SURVIVAL CURVE – pCR 
 
 
 
Figure 16. Survival curve representing the DFS and OS for pCR subsets. 
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5.16.SURVIVAL 
The five year DFS  and OS in our study were 69% and 72%. Patients 
who achieved pCR had significant survival advantage over the non-pCR 
groups in terms of DFS and OS. 
OVERALL DFS 
 
Figure 17. Survival curve   DFS- 69% 
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OVERALL SURVIVAL  
 
 
Figure 18. Survival curve  OVERALL SURVIVAL- 72% 
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OVERALL SURVIVAL pCR vs NON-pCR:   
 
 
Figure 19. Survival curve    
 OS :  pCR- 86%   Non pCR- 68%     p=0.015 
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DISEASE-FREE SURVIVAL pCR vs NON-pCR:  
 
Figure 20.Survival curves  
DFS:  pCR- 84%  Non pCR- 63%  p=0.031 
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6.DISCUSSION 
 
 The majority of patients with breast cancer are diagnosed with 
locally advanced stage in our country with poor treatment outcomes. 
With the introduction of multimodality treatment the outcomes have 
improved for these patients. In our study the incidence of stage III LABC 
was 39% and most of them are postmenopausal (56%) women. The early 
onset proposition was  9%. 
 Neoadjuvant concurrent chemoradiation  is a feasible option with 
good tolerance and improved  outcome in high risk LABC patients. 
 In our institute multimodality treatment is in practice since 1960 
and preoperative radiation for LABC was given between 1960 and 1969  
to down stage the tumor for surgery. This modality had excellent loco-
regional control, but patients succumbed to systemic failure. With the 
advent of adjuvant chemotherapy worldwide in 1970, we in our institute 
started using  neoadjuvant concurrent chemoradiation for LABC 
ensuring loco-regional and systemic control of the disease with improved 
outcomes. 
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Objectives of combining chemotherapy and radiation are 
1. Early target of micrometastasis  
2. Synergistic action in downstaging the primary tumor and nodes 
 Between 2006 and 2008 at our institute, we have treated 831 
patients with stage III breast cancer. Among them 550(66%) patients 
who received uniform concurrent chemoradiation protocol and 
completed the treatment were included for analysis. The rest of 
281(34%) patients were excluded for the following reasons,  
• 4.5% had received treatment outside (chemotherapy, surgery-
lumpectomy,  modified radical mastectomy) 
• 5% did not receive  protocol preoperative concurrent 
chemoradiation  
• 3% defaulted before starting or during the concurrent  
chemoradiation treatment 
• 6% defaulted after completing the chemoradiation protocol 
• 7% declined surgery after completing the chemoradiation 
protocol 
• 7% had progression and not completed the treatment 
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In our study 550 patients received the protocol concurrent 
chemoradiation  with 40 Gy total dose radiation to breast, axilla and /or 
supraclavicular region and one of the chemotherapy regimen. The most 
common regimen combined with radiation was FAC (62%) and other 
regimens were FEC-20%, CMF-15%, TE-3%. FAC and FEC-60 was 
most commonly used with concurrent radiation so as to keep the toxicity 
less. The concurrent chemoradiation treatment protocol was well 
tolerated. Skin toxicity was the most common reported toxicity with 
grade I-25%, grade II- 64%, grade III-3% grade IV-1% (RTOG criteria).  
Hematological toxicity in terms of low counts (Abridged common 
toxicity criteria) grade I- 1%, grade II- 14%, grade III- 15% and grade 
IV- 1.5% were reported and  febrile neutropenia were managed 
appropriately. Treatment delay during concurrent chemoradiation, more 
than 2 weeks were observed in 5% of  patients in our study. Skin and 
hematological toxicities were manageable without any mortality. 
Formenti et al studied 44 patients and reported that skin 
desquamation was the most common toxicity during or after concurrent 
RT/paclitaxel protocol. Twenty patients (20/44 - 45%) developed moist 
desquamation. Delay in  surgery was reported due to skin toxicity8.    
53 
Bapsi chakravarthy et al studied 38 patients with chemoradiation 
protocol with paclitaxel/RT. 87% completed the protocol without delay  
or dose reduction during treatment and one patient had grade 3& 4 
toxicity54. 
 Following completion of chemoradiation, skin assessment was 
done after 4 weeks and then planned for surgery followed by completion 
of the  adjuvant chemotherapy. The median treatment duration in our 
study was 6 months. 
 In our study all 550 patients had modified radical mastectomy and 
no mortality was reported. The most common surgical complication was 
seroma (20% ).  Other complications were wound infection, minimal 
wound gaping with no intervention, marginal necrosis, secondary 
suturing, skin grafting for necrosis and lymphodema. 
 Overall response rate in our study was 97% which includes 
clinical complete response 21% (115/550), partial response 
76%(418/550) and stable disease 3% (117/550). Formenti et al from 
University of Southern California Los Angeles USA studied 44 patients 
with neoadjuvant chemoradiation with paclitaxel and reported 91% 
overall response with complete response in 11%(5/44), partial response 
80%(35/44) and stable disease in 9%(4/44)8. 
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 Pathological complete response in both breast and axilla was 
achieved in 25 % (139/550) in our study. Pathological complete response 
reported in various preoperative chemoradiation protocol were 12 to 39 
% and all studies were limited by their small samples. Formenti et al 
treated 44 patients and achieved 34%(15/44) pCR, Sauter et al studied 20 
patients with pCR 12%(4/20), Bapsi chakravarthy et al reported pCR rate 
of 34%(13/38) with sample size of 38 patients and Serin et al studied 28 
patients and achieved 39% pCR(11/28)8,9,54,55. 
 In our study the incidence of pathological complete response 
showed statistical significant association with the receptor status ER 
(p=0.001), PR (p=0.001), grade of the tumor (p=0.001) and 
chemotherapy regimen (p=0.009). Other patient and tumor related 
factors like age of the patient (p=0.213), menopausal status (p=0.163), 
histology type of the tumor (p=0.617), clinical stage (p=0.308), clinical 
tumor status (p=0.092) and clinical nodal status (p=0.840) had no 
statistical correlation with pCR. The total number of chemotherapy 
cycles delivered before surgery also had no impact on achievement of 
pCR (p=0.323). 
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Several studies have shown significant association between pCR 
and long-term survival outcomes. Pathological complete response may 
represent a surrogate for disease-free and overall survival rate. 
Neoadjuvant chemotherapy had been established as conventional and 
standard of care for LABC with variable pathological response rate. The 
5 years disease free and overall survival were 36% to 61% and 49% to 
69% respectively reported by several trials for neoadjuvant 
chemotherapy protocol56,57,58,59,60. Whether pCR and its survival 
outcomes achieved after neoadjuvant chemotherapy or concurrent 
chemoradiation protocol is superior, need to be addressed by randomized 
trails.  
 Adams et al in 2010 from New York University School of 
Medicine reported that higher pCR rates correlated with superior five 
years disease free and overall survival rate for preoperative concurrent 
chemoradiation protocol with paclitaxel61. 
 In our study there is a statistically significant association between 
pCR and survival outcomes. The five year disease free and overall 
survival for all 550 treated patients were 69% and 72 %. Those who 
achieved pCR, the five year DFS-84% and OS-86% was statistically 
significant when compared with non-pCR group five year DFS-63% and 
OS-68%. (DFS  p = 0.031 and OS  p = 0.015). 
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7.CONCLUSION 
 
Multimodality treatment strategy has been established as a 
standard of care for locally advanced breast cancer. Neoadjuvant 
chemotherapy protocol was standardised as the conventional approach 
worldwide with improved long term outcomes. 
 At our institute, we are practicing multimodality approach for 
breast cancer since 1960. Our treatment policy of preoperative 
concurrent chemoradiation was a uniform protocol.It had  consistently  
showed improved outcomes for locally advanced breast cancer, from the 
present study and previous published studies from our institute. 
 All 550 patients treated with this protocol tolerated the treatment 
well without any treatment related mortality. The morbidities reported in 
our study were manageable. 
 The pathological complete response achieved in our study was  
25% comparable with 12% to 39 % reported in the literature for 
neoadjuvant concurrent chemoradiation protocol, considering the fact 
that majority in our study received anthracyclin containing regimen 
without taxanes. 
 The clinicopathological and treatment factor like receptor status 
ER/PR, grade of the tumor and the chemotherapy regimen had a 
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statistically significant association with the pathological response rate. 
The number of chemotherapy cycles received before surgery had no 
statistical impact on the pCR. 
  The five year DFS and OS was 69% and 72% respectively which 
was a better survival outcome for stage III breast cancer compared to 
world standards. Also the local and loco regional failure rates are lower 
in our study group than that reported in the literature.  
 Complete pathological response is a reliable surrogate marker of 
survival outcomes. Locally advanced breast cancer patients who are 
already at high risk for local and distant failure can have favourable long 
term survival outcomes by achieving pCR with the multimodality 
treatment approach. 
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8.ANNEXURE 
 
PROFORMA 
 
NAME:     AGE:  SEX:            
UHID NO:        CI.NO: 
POST/  PREMENOPAUSAL PARITY:  1/2/3/4/5/6/7   
AGE AT FCB:       
PREVIOUS BREAST BIOPSY: Y /N   
CLINICAL STAGE: cTNM 
FAMILY HISTORY:   DEGREE 1 / 2 / 3 
METHOD OF DIAGNOSIS: FNAC / TRUCT BIOPSY / EXCISION 
BIOPSY / INCISION BIOPSY 
HPE REPORT:  IDC / ILC/  IMC/  METAPLASTIC/ OTHERS 
GRADE :  I   /   II   /     III       NG :     LOW  /     INT  /   HIGH 
RECEPTORS:   ER: +  /  -      PR  +   /  -     CERB2 + 1  /  2  / 3               
P53        CATEPSIN    (CYTOLOGY / HPE)  
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METASTATIC WORK UP: 
 CXR: NORMAL/ABNORMAL FINDINGS IF ANY 
 BONE SCAN: NORMAL/ABNORMAL FINDINGS  
 USG LIVER: 
 USG PELVIS:  
 OTHERS:  MAMMOGRAM    CT CHEST-    
PERFORMANCE STATUS- 1  /2   
TREATMENT DETAILS:  
DATE OF INITIATION OF TREATMENT: 
NEOADJUVANT TREATMENT: (PROTOCOL ) 
CONCURRENT RT+CT / INDUCTION CT – RT 
CHEMOTHERAPY: 
 TYPE AND DOSE: CMF     / FAC     / FEC     / AC   / TE 
 NO OF CYCLES: 
        BEFORE RT: 
                DURING RT: 
                AFTER RT :TOXICITY: FEVER /  LOW COUNTS-      
   GRADE 1 /2/3           DELAY- 
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RADIATION: 
 TECHNIQUE: 
 SITE: RT  / LT – BREAST  / AXILLA  /  SCL    / IMR 
 DOSE: 
 DATE: 
 ANY DELAY / INTERRUPTION: 
 SKIN TOXICITY: GRADE    I  /     II   /    III   /    IV 
 
ASSESSMENT OF CLINICAL RESPONSE: 
 COMPLETE / PARTIAL / STABLE  / PROGRESSION 
 
SURGERY: 
 DATE OF SURGERY: 
 TYPE OF SURGERY: MRM + AXILLA  LEVEL 1,2,3 
COMPLICATIONS: SEROMA / GAPPING / NECROSIS/ 
RESTRICTED ARM MOVEMENTS/ LYMPHEDEMA  
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HPE: 
TUMOUR NODES 
RESIDUE (YES  / NO) TOTAL -  
SITE – UOQ/UIQ/LOQ/LIQ/CS LEVEL I 
SIZE: ____________ LEVEL II 
MARGIN__________ LEVEL III 
LVSI -  Y / N            SKIN/ NIPPLE 
– Y /N PNS                      
 
PCR: Y / N  PATHOLOGICAL STAGE – p T    N     
ADJUVANT TREATMENT: 
 CHEMOTHERAPY-  CMF/FAC/FEC/TE/AC       
 RADIOTHERAPY – SCL / IMR 
 HORMONE THERAPY: TAMOXIFEN  / LETRAZOLE  
RECURRENCE: IF ANY 
LOCAL / REGIONAL / SYSTEMIC / LOCAL AND REGIONAL / 
LOCAL AND SYSTEMIC / 
REGIONAL AND SYSTEMIC  
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DATE OF DIAGNOSIS OF RECURRENCE: 
CONFIRMATION OF RECURRENCE: 
 CYTOLOGY / BIOPSY / IMAGING / NONE 
TREATMENT OFFERED: 
 SURGERY: 
 CHEMOTHERAPY 
 RADIATION 
 HORMONE THERAPY 
 SUPPORTIVE CARE ONLY 
PROGRESSION IF ANY AND TREATMENT OFFERED: 
LAST VISIT AT OPD: 
STATUS AT FOLLOW UP: 
DISEASE FREE/ ALIVE WITH DISEASE / DIED OF DISEASE/ 
DIED OF OTHER REASONS/ LOST TO FOLLOW UP 
DFS: 
OVERALL SURVIVAL: 
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